HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintained a $36 price target.
March 01, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on 4D Molecular Therapeutics with a $36 price target.
The reiteration of a Buy rating and maintenance of a $36 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors and potentially lead to a positive short-term impact on FDMT's stock price. The analyst's bullish stance suggests a strong belief in the company's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100